Fig. 6.
After coronary artery ligation surgery, vehicle-treated mice had a significant enlargement of the left and right ventricles [LVEDD, LVESD, and right ventricular end-diastolic area (RVEDA)] and a significant reduction in left and right ventricular function (LVEF, MPI, and TAPSE). Treatment with GS-6201 (4 mg i.p. twice daily for 14 days) significantly limited the cardiac enlargement and dysfunction. *, P < 0.001 versus baseline (or sham); +, P < 0.001 versus vehicle.